Tonix Pharmaceuticals Faces Stock Plunge Amid Reverse Split and FDA Decision Awaiting
1206+ Words Refined into 6 Facts by AI • 1 source • 58m ago
Show Full Summary
- Tonix Pharmaceuticals stock fell sharply after a 1-for-100 reverse stock split.
- Shares dropped 54% to $0.19 on February 3rd, 2025.
- Awaiting FDA decision on TNX-102 SL for fibromyalgia by August 15th, 2025.
- Tonix submitted a New Drug Application in October 2024.
- Secured $34 million contract for TNX-4200 antiviral development.
- Only one analyst has set a 12-month price target for TNXP recently.
The sources of this summary are listed below. Click to view.